ACR Image Metrix Completes Successful Second Year as Imaging CRO


Philadelphia, PA - September 22, 2009

ACR Image Metrix, an imaging contract research organization (CRO), exceeded its goals by initiating projects for over 30 pharmaceutical, biotechnology and medical device companies through its second full year of operation.  Many of these awarded projects were “repeat” business from their existing client base. ACR Image Metrix, a leader in imaging trial design, techniques, data extraction, management and analysis, was launched as a for-profit division of the American College of Radiology® (ACR) in 2007 with profits being reinvested into the ACR Clinical Research Center.

“The value of imaging in clinical trials is evident and is paving the way for better integration of molecular, functional and volumetric imaging in the drug discovery process," said Mike Morales, ACR Image Metrix general manager.

“This year we also expanded our office space and core imaging laboratories, allowing us greater capacity to handle larger global research projects,” said Veronique Cardon, ACR Image Metrix director of business development.    

The 10,000 square-foot facility also includes two learning laboratories designed for researchers to acquire the knowledge and skills needed to perform advanced imaging techniques.  The core imaging laboratory has evolved to include a focus on the increasing challenges associated with advanced imaging capabilities in imaging clinical research today.  These advanced imaging techniques include DCE-MRI, diffusion weighted/tensor imaging, FDG and FLT-PET and many more. In addition, ACR Image Metrix also offers services to the medical device industry in conducting clinical research to secure regulatory approvals for their new devices and software products such as CAD (computer aided detection).

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Related Content
© 2024 MJH Life Sciences

All rights reserved.